Ailomics

Ailomics Therapeutics Co., Ltd. was founded in July 2022 as a startup company dedicated to innovative drug development. Ailomics leverages its groundbreaking computational biology platform to conduct in-depth analysis of multi-omics data from patients, identifying new mechanisms and drug targets that drive disease progression, and developing innovative drugs. Based on a deep understanding of disease biology, Ailomics is committed to the research and development of innovative drugs targeting immune diseases and cancers with significant clinical needs.